TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Feasibility of MTT
Endpoint domain: Resource use
Primary endpoint: Peripheral Capillary Oxyhemoglobin Saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monocular logMAR Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of acute care visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Participants with Adverse Event (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Abnormalities in Clinical Laboratory Assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cord blood phoenixin-14 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adipocyte function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fat storage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in hip external rotation strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Specificity of intraoperative ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sensitivity of intraoperative ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in gut microbiota concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: SpO2 value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of Graves' disease (GD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of severe or medically significant Adverse and Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in headache days
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Unexpected abortion
Endpoint domain: Mortality/survival
Primary endpoint: Proptosis responder rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Limited function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Objective Assessment of Phonatory Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cortical Excitability (intrahemispheric inhibition)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Treatment-emergent potentially clinically significant abnormalities (PSCAs) in blood pressure (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Treatment-emergent potentially clinically significant abnormalities (PSCAs) in pulse rate (bpm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Forced Expired Volume in one second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Weekly weight gain in pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total weight gain in pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Toolkit assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Total Calorie Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants with Treatment-Emergent Adverse Events (Any-grade and Grade >= 2)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with Treatment-Emergent Interstitial Lung Disease (ILD)
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Response (OR) by Blinded Independent Central Review (BICR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Quality of life for cancer patients
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life for colorectal cancer
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life for anal cancer
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of patients alive and without respiratory failure
Endpoint domain: Mortality/survival
Primary endpoint: Changes in Autism Diagnostic Observation Schedule-Second Edition scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the number of seizures or epileptic seizures during the study period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Neurophysiological changes: in functional activity and brain anatomy using Magnetic Resonance Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Moderate-Vigorous Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Titers of influenza vaccine antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of participants reporting solicited injection site reactions and systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Index client fidelity assessment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Contact clients tested
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cost per person living with HIV diagnosed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Discharge disposition
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in patient reported fatigue severity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Hypertension Self-Care Profile
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hill-Bone Hypertension Treatment Compliance Scale
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Healthy Lifestyle Behaviors Scale II
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Episodes of hypoglycaemia requiring intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of neonatal hypoglycaemia
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse Events per Common Terminology Criteria for Adverse Events (NCI-CTCAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of acute grade 2-4 graft versus host disease (GVHD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Experiential negative symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Functional Status: Knee Injury and Osteoarthritis outcome score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pain: Numeric Pain Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ADAS-Cog 14 score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: survival in patients with severe alcoholic hepatitis
Endpoint domain: Mortality/survival
Primary endpoint: Number of Deaths During Hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants that Require Amputation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants with Amputation-free survival
Endpoint domain: Mortality/survival
Primary endpoint: 6-month Progression free survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Composite of ischemic and bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of CTG triplet repetitions in the TCF4 gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Within-Subject Difference in Daily Sleep Duration
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Clinical bond failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Necessity of heterocatheterization within 24 hours following cesarean section
Endpoint domain: Adverse events/effects
Primary endpoint: Emergency Delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Half-life (t½) of efanesoctocog alfa, damactocog alfa pegol and turoctocog alfa pegol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete remission of cutaneous warts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: overall ocular comfort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction of time constant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion with positive test result among participants with HIV, HBV or HCV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion with negative index test result among participants without HIV, HBV or HCV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in food insecurity severity
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: peak pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pressure-time integrals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ED50 and ED95 of remimazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with MI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants with unplanned repeat revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: NAS sign scoring scale of Thongprasom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the Self-rating Anxiety Scale (SAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Perceived competence in Diabetes (PCS-5)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasma concentrations of rongliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's response
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients with IHC 1+ or IHC 2+/ISH- HER2 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of patients with IHC>0<1+ or IHC null (no stain at all) HER2 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of participants achieving blood pressure < 140/90 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Subjective appetite rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in HPV Vaccine Recommendation Quality Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Appetite feeling
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Persistent disability or death by 90 days
Endpoint domain: Mortality/survival
Primary endpoint: Change in DASI Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Dry Skin Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in PGA Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Lactic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Indicators of infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: C-reaction protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Help-seeking behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Experienced need
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Barriers
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Success rate of first fURS insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Expression of genes encoding ERK5 and PKM2 kinases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety modulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Depression modulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mind wandering modulation
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of Words and Numbers Correctly Identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal Structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline VO2max as percentage of predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in size of granular corneal deposits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ORR
Endpoint domain: Physiological/clinical
Primary endpoint: Number of participants adhering to TRE protocol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Dental Implant bone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dental implant radicular bone thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of approached participants that meet eligibility criteria
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of approached and eligible participants that provide informed consent
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of participants that adhere to the intervention as prescribed among participants that start the intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of subjects with adverse events, serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of subjects with clinically significant changes in hematology parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of subjects with clinically significant changes in biochemistry parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of subjects with clinically significant changes in urinalysis parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of subjects with clinically significant changes in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of mucosal ulcerations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: End of treatment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Systemic microvascular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Systemic macrovascular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left ventricle global longitudinal strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cutaneous Sensory Block Area (CSBA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first event of ischemic stroke or systemic embolism
Endpoint domain: Mortality/survival
Primary endpoint: Time to first occurrence of BARC type 3c/5 bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in Proteinuria Based on 24-hour Urine Protein Creatinine Ratio (UPCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence Rate for Malignancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Biochemical marker of stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fMRI blood oxygen level dependent (BOLD) response to food commercials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fMRI blood oxygen level dependent (BOLD) response to toy commercials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline DXA analysis for total body fat mass of child at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of clinical complete response (cCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of pathological minimal residual disease (pMRD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With AEs by Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline Danish Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline ICIQ-UI SF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: POAF incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Identification of focal BBBD in the seizure onset zone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety profile of mangafodipir administration
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with Clinical Remission at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with Endoscopic Response at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in PACC-5 Total Scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Intraosseous defect depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Respiratory Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Blood glucose following the OGTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Volume of e-liquid used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: IGA-CHE treatment success at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrasound aorta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Ultrasound of the carotid arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Ultrasound of the femoral arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rate of participants with PSA decline to < 0.2 ng/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients achieving cytopenia responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Trail-Making Test, Part B (TMT-B)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Stroop Color and Word Test, color-word condition (SCWT-CW)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Precision of the EBC device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of the EBC device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average number of daily steps
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percent change in SALT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Manual Muscle Test (MMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease remission status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from Baseline Sunnybrook
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Glasgow Outcome score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: DL model accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change from baseline in the mMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pediatric Anxiety Rating Scale modified for ASD (PARS-ASD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mammary nucleus minification or disappearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: stringent Complete Response (sCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Filter/system useful life
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Moderate to severe chronic graft versus host disease (GVHD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: recommended Phase 2 dose (RP2D) or maximum tolerated dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bias and percent error of SjO2 measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Pressure during hemodialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes